BlackRock’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

BlackRock’s Portfolio CADX Stock Details CADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-1,691	Closed	-$15K	–	3220
2013 Q4	$15K	Hold	1,691	–	–	﹤0.01%	2525
2013 Q3	$11K	Hold	1,691	–	–	﹤0.01%	2622
2013 Q2	$12K	Buy	+1,691	New	+$11.8K	﹤0.01%	2570

Other funds holding CADX

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock's CADX Position: Q1 2014 in Review

BlackRock sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 1,691 shares — an estimated $15K sold.

BlackRock first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $15K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

BlackRock reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
BlackRock sold 1,691 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $15K.
BlackRock first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
BlackRock's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $15K in Q4 2013.
3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on BlackRock's 13F filing for Q1 2014, filed 2 May 2014.